• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Download
Number Citation Analysis
1
Costa EC, Artigas L, Martinez-Cardús A, López A, Camprodon MC. 141P Unveiling the likely pharmacological mechanisms of brigatinib on brain metastasis in ALK+ patients with non-small cell lung cancer: A systems biology and artificial intelligence-based approach. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00396-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
2
Ahn MJ, Kim SW, Costa EC, Rodríguez L, Oliveira J, Insa Molla M, Majem M, Costa L, Su WC, Lee K, Yang JH, Spigel D, Cho E, D'Arcangelo M, Campelo MG, Delmonte A, Mitchell P, Achour I, Subramaniam D, Felip E. LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
3
Ghiringhelli F, Barre P, Pichon E, Ponce Aix S, Juan Vidal O, Carcereny Costa E, Sethi T, Lindmark B, MacKinnon A, Aslanis V, Phung D, Jensen P, Rajiwate Z, Ross G, Basse L. 1192TiP GALLANT-1: Galectin-3 (Gal-3) inhibitor, GB1211, plus atezolizumab (atz) in patients (pts) with non-small cell lung cancer (NSCLC) - a dose finding study followed by a randomised, double-blind, placebo-controlled trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1315] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
4
Garcia Campelo M, Domine Gomez M, De Castro Carpeno J, Moreno Vega A, Ponce Aix S, Arriola E, Carcereny Costa E, Majem Tarruella M, Huidobro Vence G, Esteban Gonzalez E, Fuentes Pradera J, Ortega Granados A, Guillot Morales M, Massuti Sureda B, Vila Martinez L, Blasco Cordellat A, Fajardo C, Crama L, Lerones Laborda N, Cobo Dols M. 1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
5
Ponce Aix S, Carcereny Costa E, Bosch-Barrera J, Felip Font E, Guirado M, Coves Sarto J, Majem Tarruella M, Juan Vidal O, Dalmau Portulas E, Diz P, Ortega Granados A, Domine Gomez M, Blasco Cordellat A, Mosquera Martinez J, Sala Gonzalez M, Dorta M, Calvo de Juan V, Zugazagoitia J, Enguita A, Paz-Ares L. 160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]  Open
6
Martinez-Marti A, Majem M, Barlesi F, Carcereny Costa E, Chu Q, Monnet I, Sanchez A, Dahkil S, Camidge D, He P, Soo-Hoo Y, Cooper Z, Kumar R, Bothos J, Aggarwal C, Herbst R. LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.2121] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]  Open
7
Krebs M, Helland Å, Carcereny Costa E, Arriola Aperribay E, Dómine Gómez M, Trigo Pérez J, Thompson J, Strauss J, Ortega Granados A, Felip E, Schmidt E, Chisamore M, Madeleine N, Rayford A, Lorens K, Siddiqui A, Gabra H, Nautiyal J, Micklem D, Lorens J, Spicer J. OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.275] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
8
Calvo V, Carcereny Costa E, Guirado M, Ortega Granados A, Lopez Castro R, Rodriguez-Abreu D, Garcia Campelo R, del Barco Morillo E, Juan-Vidal O, Camps C, Gonzalez-Larriba J, Domine Gomez M, Trigo Perez J, Cobo Dols M, Cerezo Gonzalez S, Calzas Rodriguez J, Massuti Sureda B, Bosch-Barrera J, Moran T, Provencio Pulla M. 1794P Extensive stage (ES) small-cell lung cancer (SCLC) in Spain: A review of demographic, epidemiological and clinical data from the Thoracic Tumors Registry (TTR study). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]  Open
9
Carcereny Costa E, Calvo V, Guirado M, Ortega Granados A, Lopez Castro R, Rodriguez-Abreu D, Mosquera Martinez J, del Barco Morillo E, Juan-Vidal O, Sanchez Hernandez A, Sala Gonzalez M, Blanco Guerrero R, Bernabe Caro R, Alonso R, Garcia Benito C, Oramas Rodriguez J, Diz Tain P, Nogueron Martinez E, Guirao Rubio C, Provencio Pulla M. 1786P Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
10
Michels S, Massuti Sureda B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohe C, Rodríguez-Abreu D, Bischoff H, Carcereny Costa E, Corral Jaime J, Insa A, Reck M, Scheffler M, Karachaliou N, Merkelbach-Bruse S, Nogova L, Büttner R, Rosell R, Wolf J. Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial – Updated progression-free survival, overall survival and mechanisms of resistance. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.070] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
11
Carcereny Costa E, Guirado M, Camps Herrero C, Bosch Barrera J, García-Campelo MR, Ortega Granados A, Gonzalez-Larriba J, De Dios Alvare N, Domine Gomez M, Massuti Sureda B, Sala M, Bernabé R, Oramas Rodriguez J, del Barco Morillo E, Padilla A, Aguiar Bujanda D, Cerezo Gonzalez S, Lopez Castro R, Rodriguez Abreu D, Provencio M. Tobacco use in lung cancer (LC) patients (p) in Spain. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz266.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
12
Trigo Perez J, Felip E, Brunsvig P, Helland A, Viñolas N, Ponce Aix S, Carcereny Costa E, Domine Gomez M, Arriola E, Garcia Campelo R, Spicer J, Thompson J, Ortega Granados A, Holt R, Lorens J, Shoaib M, Siddiqui A, Schmidt E, Chisamore M, Krebs M. Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz260.098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
13
Rodriguez Abreu D, Guirado M, Camps Herrero C, Bosch Barrera J, Bernabé R, Casal J, García-Campelo MR, Gonzalez-Larriba J, Massuti Sureda B, Ortega Granados A, Domine Gomez M, Sala M, Padilla A, Del Barco Morillo E, Oramas Rodriguez J, Blanco Guerrero R, Aguiar Bujanda D, López Castro R, Carcereny Costa E, Provencio M. Biomarker testing of lung cancer in Spain. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz266.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
14
Angelats L, Garcia Campelo M, Bernabe Caro R, Arriola Aperribay E, Calvo de Juan V, Barba Joaquín A, Vinolas Segarra N, Gil Moreno M, Vilà Martinez L, Juan Vidal O, Vilariño Quintela N, Cobo M, Sais E, Domine Gomez M, Fernandez Nuñez N, Coves Sarto J, Marse Fabregat R, Esteve Gomez A, Rodríguez-Abreu D, Carcereny Costa E. Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz063.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
15
Carcereny Costa E, Rodriguez-Abreu D, Guirado M, López-Castro R, Massutí B, Bosch Barrera J, Nogueron Martnez E, Sala Gonzalez M, Domine Gomez M, Del Barco Morillo E, Cerezo Gonzalez S, Dorta Suarez M, Casal Rubio J, Camps C, Muñoz M, de las Peñas R, Ortega dominguez J, Gonzalez-Larriba J, Bernabe Caro R, Provencio Pulla M. First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
16
Karachaliou N, Lefterova M, Draper J, Molina MA, Chaib I, Palmero R, Taus A, Viteri S, González Cao M, Majem Tarruella M, Carcereny Costa E, Moran T, Garde Noguera J, Felip Font E, Olsen S, Jackson M, Sampayo M, Faull I, Dix D, Rosell R. Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy304.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
17
Palmero R, Taus Á, Majem Tarruella M, Viteri S, Carcereny Costa E, Garde J, Felip Font E, Cassidy C, Dix D, Karachaliou N, Rosell R. Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
18
Remon J, Martinez-Marti A, Carcereny Costa E, Zeron-Medina Cuairan J, Sansano I, Mate J, Pardo N, Cedres S, Navarro A, Martinez de castro A, Moran T, Felip Font E. Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx381.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
19
Erasun Lecuona C, Moran Bueno M, Vila L, Teruel I, Angelats L, Ferrando A, Plaja A, Torres P, Lopez E, Muriel R, Muñoz-Marmol A, Mate J, Velarde J, Carcereny Costa E. KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.040] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
20
Popat S, Ardizzoni A, Ciuleanu T, Cobo Dols M, Laktionov K, Szilasi M, Califano R, Carcereny Costa E, Griffiths R, Paz-Ares L, Szczylik C, Corral J, Isla D, Jassem J, Appel W, Van Meerbeeck J, Wolf J, Jiang J, Molife L, Felip Font E. Nivolumab in previously treated patients with metastatic squamous NSCLC: Results of a European single-arm, phase 2 trial (CheckMate 171) including patients aged ≥70 years and with poor performance status. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
21
Erasun Lecuona C, Moran Bueno M, Vila L, Teruel I, Angelats L, Ferrando A, Plaja A, Torres P, Lopez E, Muriel R, Muñoz-Marmol A, Mate J, Velarde J, Carcereny Costa E. KRAS mutations (KRAS-mut) and antiPD1/PDL1 therapy in a cohort of non-small cell lung cancer (NSCLC) patients (p): Experience from a single institution. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx376.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
22
Peters S, Carcereny Costa E, Garassino M, Christoph D, Kurata T, Chaft J, Johnson M, Mocci S, Gettinger S, Felip E. Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx091.004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
23
Eberhardt W, Garassino MC, Rizvi NA, Besse B, Jänne PA, Peters S, Keong Toh C, Kurata T, Carcereny Costa E, Koczywas M, Felip Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson ML. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017. [DOI: 10.1055/s-0037-1598277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
24
Costa EC, Dantas TCB, de Farias Junior LF, Frazão DT, Prestes J, Moreira SR, Ritti-Dias RM, Tibana RA, Duhamel TA. Inter- and Intra-Individual Analysis of Post-Exercise Hypotension Following a Single Bout of High-Intensity Interval Exercise and Continuous Exercise: A Pilot Study. Int J Sports Med 2016;37:1038-1043. [PMID: 27676151 DOI: 10.1055/s-0042-112029] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
25
Rocha RMP, Alves AMCV, Lima LF, Duarte ABG, Chaves RN, Brito IR, Costa EC, Bernuci MP, Rosa-e-Silva ACJS, Xu M, Rodrigues APR, Campello CC, Figueiredo JR. Is the mouse follicle culture a good model for the goat with respect to the development of preantral follicles in vitro? Domest Anim Endocrinol 2014;49:27-30. [PMID: 25010025 DOI: 10.1016/j.domaniend.2014.04.005] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2014] [Revised: 04/24/2014] [Accepted: 04/25/2014] [Indexed: 10/25/2022]
26
Karachaliou N, Drozdowskyj A, Gimenez-Capitan A, Morales-Espinosa D, Moran T, Costa EC, Cobo M, Domine M, Bover I, Camps C, Pulla MP, Vergnenegre A, Lopez-Vivanco G, Tarruella MM, Viteri S, Sureda BM, Rosell R. Palb2 Mrna Expression As a Predictive and Prognostic Marker in Advanced Non-Small-Cell Lung Cancer (Nsclc) Patients (P) Treated with Cisplatin- Docetaxel Chemotherapy. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu326.20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
27
Massuti B, Jimenez U, Rodriguez Paniagua JM, Pun YW, Cobo M, Carcereny Costa E, Arrabal R, Astudillo J, Barneto IC, De Las Penas R, Baamonde C, Sales G, Gonzalez-Larriba J, Lopez-Vivanco G, Hernando-Trancho F, Pac J, Artal-Cortes A, Rivas J, Rosell R, Sanchez JM. SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
28
Carcereny Costa E, Provencio Pulla M, Cubedo Cervera R, Sánchez Ruiz A, Sánchez Vegazo I, González Hernando C, Cantos Sánchez de Ibargüen B, Espinosa Aunión R. [Patient with double lung lesion and history of renal adenocarcinoma]. Rev Clin Esp 2004;204:379-80. [PMID: 15274786 DOI: 10.1157/13063532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
29
Carcereny Costa E, Provencio Pulla M, Cubedo Cervera R, Sánchez Ruiz A, Sánchez Vegazo I, González Hernando C, Cantos Sánchez de Ibargüen B, Espinosa Aunión R. Paciente con doble lesión pulmonar y antecedentes de adenocarcioma renal. Rev Clin Esp 2004. [DOI: 10.1016/s0014-2565(04)71490-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
30
Weigand O, de Souza AZ, Okawara H, Costa EC, Salvatore CA. [Post-mastectomy rehabilitation]. AMB Rev Assoc Med Bras 1982;28:143-7. [PMID: 6984942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA